Business description: Amarin Corporation plc

Amarin Corporation PLC is a pharmaceutical company. The Company is focused on the commercialization and development of therapeutics to improve cardiovascular (CV), health and reduce CV risk. The Company operates through the development and commercialization of VASCEPA. Its lead product, Vascepa (icosapent ethyl) capsule is used as an adjunct to diet to reduce triglyceride levels in adult patients with severe hypertriglyceridemia. This indication for Vascepa, known as the MARINE indication, is based primarily on the results from the MARINE study of Vascepa in this approved patient population. The Company sells Vascepa principally to wholesalers, as well as selected regional wholesalers and specialty pharmacy providers, or collectively, its distributors, which in turn resell Vascepa to retail pharmacies for resale to patients and healthcare providers.

Number of employees: 80

Sales by Activity: Amarin Corporation plc

Fiscal Period: December 2021 (USD) 2022 (USD) 2023 (USD) 2024 (USD) 2025 (USD)

Development and Commercialization of Vascepa

583M 369M 307M 229M 214M

Geographical breakdown of sales: Amarin Corporation plc

Fiscal Period: December 2021 (USD) 2022 (USD) 2023 (USD) 2024 (USD) 2025 (USD)

US

- - - - 154M

Unallocated

- - - - 30.89M

Europe

- - - - 18.37M

Rest of the World

- - - - 10.24M

Executive Committee: Amarin Corporation plc

Manager TitleAgeSince
Chief Executive Officer 63 2024-06-03
Director of Finance/CFO 42 2024-10-22
Compliance Officer 56 2023-11-14
Chief Operating Officer 59 2025-10-16
Chief Tech/Sci/R&D Officer - 2022-03-31

Composition of the Board of Directors: Amarin Corporation plc

Director TitleAgeSince
Director/Board Member 63 2024-06-03
Director/Board Member 43 2023-02-27
Director/Board Member 67 2023-02-27
Chairman 51 2023-03-26
Director/Board Member 47 2023-02-27
Director/Board Member 64 2023-02-27
Director/Board Member 47 2025-04-06

Shareholders: Amarin Corporation plc

NameStocks%Valuation
Sarissa Capital Management LP
8.081 %
1,673,395 8.081 % 22 M $
Sarissa Capital Management LP
6.216 %
1,287,195 6.216 % 17 M $
Acadian Asset Management LLC
3.482 %
720,984 3.482 % 9 M $
Kynam Capital Management LP
2.574 %
532,982 2.574 % 7 M $
Morgan Stanley Capital Services LLC
1.08 %
223,617 1.08 % 3 M $
NameStocks%Valuation
JEC II Associates LLC
0.7252 %
3,000,000 0.7252 % 39 M $
0.4472 %
1,850,000 0.4472 % 24 M $
0.4141 %
1,712,960 0.4141 % 22 M $
0.2064 %
853,600 0.2064 % 11 M $
0.0651 %
269,400 0.0651 % 4 M $

Company details: Amarin Corporation plc

Amarin Corp. Plc

One Central Plaza

2, Dublin

+353 0 166 99020

http://www.amarincorp.com
address Amarin Corporation plc(AMRN)

Bio Therapeutic Drugs

Change 5-day change 1-year change 3-year change Capi.($)
+6.65%+10.73%-32.71%-7.64% 252M
+0.65%-3.56%+33.53%+60.50% 63.48B
+1.76%+1.27%+11.82%+81.21% 54.55B
-0.94%+0.77%+8.85%+100.19% 53.59B
+2.76%+0.87%+27.92%+55.07% 44.75B
+2.00%-3.39%+17.83%+119.04% 41.62B
+1.34%-2.86%+224.43%+914.08% 39.91B
+0.64%-3.85%+11.71%+45.57% 32.47B
+29.06%+48.65%+106.84%+92.73% 26.7B
+3.72%-7.45%+24.25%-2.99% 23.36B
Average +4.76%+0.03%+43.45%+145.78% 38.07B
Weighted average by Cap. +3.24%-0.29%+47.25%+161.36%
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
MarketScreener Ratings - Amarin Corporation plc
Sell
Consensus
Buy
Mean consensus
SELL
Number of Analysts
2
Last Close Price
12.74USD
Average target price
12.50USD
Spread / Average Target
-1.92%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Amarin Corporation plc
  1. Stock Market
  2. Stocks
  3. AMRN Stock
  4. Company Amarin Corporation plc